<span id="midArticle_start"/>May 5 (Reuters) - Biotec Pharmacon ASA :
<span id="midArticle_0"/>* Q1 sales revenue 12.3 million Norwegian crowns ($1.62 million) versus 4.1 million crownsyear ago
<span id="midArticle_1"/>* Q1 EBITDA loss 2.8 million crowns versus loss 7.1 million crowns year ago
<span id="midArticle_2"/>
<span id="midArticle_3"/>Source text for Eikon:
<span id="midArticle_4"/>Further company coverage:
<span id="midArticle_5"/>($1 = 7.5970 Norwegian crowns) (Gdynia Newsroom)
<span id="midArticle_6"/>
<span id="midArticle_0"/>* Q1 sales revenue 12.3 million Norwegian crowns ($1.62 million) versus 4.1 million crownsyear ago
<span id="midArticle_1"/>* Q1 EBITDA loss 2.8 million crowns versus loss 7.1 million crowns year ago
<span id="midArticle_2"/>
<span id="midArticle_3"/>Source text for Eikon:
<span id="midArticle_4"/>Further company coverage:
<span id="midArticle_5"/>($1 = 7.5970 Norwegian crowns) (Gdynia Newsroom)
<span id="midArticle_6"/>
via Smart Health Shop Forum http://ift.tt/1ETzSfI
No comments:
Post a Comment